BriaCell Unveils Six ASCO 2026 Presentations with Phase 2 Survival Data
BriaCell will present six clinical data presentations at the 2026 ASCO Meeting, including three posters detailing Phase 2 Bria-IMT survival and quality of life outcomes in advanced metastatic breast cancer and three publication-only abstracts on immunotherapy advances and biomarker analyses. Scheduled sessions run May 30–June 2 in Chicago.
1. Upcoming ASCO 2026 Presentations
BriaCell will showcase six clinical data presentations at the ASCO Annual Meeting in Chicago from May 29 to June 2, 2026, including three poster sessions and three publication-only abstracts highlighting its immunotherapy pipeline.
2. Phase 2 Bria-IMT Survival and QOL Data
Poster boards 221 and 222 will present final randomized Phase 2 Bria-IMT combined with checkpoint inhibitors survival rates at 12 and 24 months and quality of life results in advanced metastatic breast cancer.
3. Phase 3 Biomarker Predictors of Response
Poster board 442 will detail ongoing analyses from the randomized Phase 3 Bria-ABC trial evaluating blood-based biomarkers as early predictors of progression-free survival in the same patient population.
4. Publication-Only Abstracts on Next-Gen Immunotherapies
Three publication-only abstracts will cover BC1 second-generation cell-based immunotherapy, liquid biopsy stratification of metastatic breast cancer risk, and PD-L1 expression monitoring in circulating cancer-associated cells.